Summary: Healthline provides a well-rounded overview about the basics of psychedelic-assisted therapy, including the current research applications and statuses of various psychedelics, stages of the therapeutic process, and potential risks associated with psychedelic use.
The article highlights MAPS’ most recent clinical trial involving MDMA-assisted therapy for the treatment of PTSD, which “was the first [Phase] 3 trial of any psychedelic-assisted therapy.”
“There’s still a lot to learn about the potential of psychedelic therapy,” concludes Healthline, “but the existing research is promising, particularly for those with severe PTSD.”
Originally appearing here.
